Your SlideShare is downloading. ×
Artemisinin
Artemisinin
Artemisinin
Artemisinin
Artemisinin
Artemisinin
Artemisinin
Artemisinin
Artemisinin
Artemisinin
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
199
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
8
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Epidemiology of Malaria drug-resistant malaria is a rapidly spreading global health threat Malaria is a public health problem today in more than 90 countries, inhabited by 2,400 million people – 40% of the world’s population An estimated 300 to 500 million cases each year cause 1.5 to 2.7 million deaths, more than 90% of which occur in children under age 5 in Africa. Malaria kills one child every 30 seconds Progresses made in the last 50 years in restricting the geographical areas affected by malaria are being eroded recently, due to changes in land use, global climate changes, armed conflicts/movement of refugees, easy international travel and development of multi-drug resistant strains of parasite. The vast majority of areas of endemic malaria show resistance to chloroquine (the oldest, cheapest treatment). Resistance to sulfadoxine-pyrimidine is emerging in most affected areas. Resistence to mefloquine has been observed in South-east Asia (areas of multi-drug resistance) No malaria Malaria present only in small, remote areas. No chloroquine-resistant P.falciparum. Malaria transmision areas Intermediate malaria risk, no chloroquine-resistant strains of P.falciparum. Multidrug resistance areas Intermediate malaria risk, but chloroquine-resistance of P.falciparum is Chloroquine resistance areas conf irmed. Malaria-f ree islands Sulf adoxine –py rimethamine resistance areas High risk area f or chloroquine-resistant Plasmodium falciparum. No clinically relevant resistance has been observed with artemisinin and related derivatives 1
  • 2. 2
  • 3. 3
  • 4. 4
  • 5. 5
  • 6. 6
  • 7. 7
  • 8. 8
  • 9. 9
  • 10. 10

×